Eliot Forster, F-star CEO

As­traZeneca takes a chance on the STING path­way with F-star

Af­ter a slew of Big Phar­ma com­pa­nies and biotechs walked away from the STING path­way in the last few years, As­traZeneca is ap­proach­ing the field …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.